• Contact us
  • Young GI
  • Patients
  • Industry
  • Press
Create myUEG account
  • About
    • To landing page
      • Who we are
      • Boards & Committees
      • Governance
      • Secretariat
      • What we do
      • Strategic Drivers
      • Annual Report
      • Our Members
      • Specialist Member Societies
      • National Member Societies
      • Community
      • myUEG
      • Women in GI
      • Young GIs
  • Week
    • To landing page
      • Register
      • Fees
      • CME Accreditation
      • Science
      • Abstracts
      • Programme
      • Postgraduate Teaching
      • Networking
      • Industry Programme
      • Acknowledgements
      •  
      • Congress Resources
      • Week 24/7 recordings
  • Education
    • To landing page
      • Online Education
      • Online Courses
      • Webinars
      • Virtual Summer School
      • Face-to-face Education
      • Masterclass
      • Clinical Visiting Fellowships
      • Education Resources
      • Mistakes in...
      • Articles
      • Image Hub
      • CME in Europe
  • Research
    • To landing page
      • Support
      • Research Prize
      • Research Fellowship
      • Horizon Europe Support
      • Researchers Network
      • Research Switchboard
      • Advocacy
      • Position Papers
      • White Book
  • Quality of Care
    • To landing page
      • Search Guidelines
      • Standards & Guidelines Repository
      • Non-English Guidelines
      •  
      • GI Guidelines App
      • Develop & Implement
      • Essentials for a good guideline
      • Get Funding
      • Guideline Webinars
      • Projects
      • Quality of Care Initiatives
      • Quality Standards
  • Public Affairs
    • To landing page
      • Advocacy
      • Manifesto on Digestive Health
      • Core Positions
      • Position Papers
      • Stakeholder Collaboration
      • MEP Digestive Health Group
      • Key Topics
      • Our Supporters
      • #EUNewsline →
  • Publications
    • To landing page
      • Publications
      • Congress Publications
      • Research Publications
      • Public Affairs Publications
      • Education Publications
      • UEG Publications
      • UEG Journal →
      • UEG Journal Podcast
  • Opportunities
    • To landing page
      • Congress Opportunities
      • National Scholarship Awards
      • Best Abstract Prizes
      • Research Funding
      • Research Prize
      • Research Fellowship
      • Researchers Network
      •  
      • Activities Funding
      • Career Development
      • Rising Star Awards
      • Clinical Visiting Fellowships
      • Open Positions
      • Talent Pool
      • Recognition of Achievements
      • Lifetime Achievement Award
      • Journal Best Paper Award
  • Library
    • To landing page
      • Congress Resources
      • Week 24/7 recordings
      • Abstracts
      • Posters
      • Guideline Resources
      • Education Resources
      • Image Hub
      • Webinars
      • Education articles
  • Contact us
  • Young GI
  • Patients
  • Industry
  • Press
Head-to-Head

Liver biopsy for evaluation of fibrosis in chronic liver disease: Yes or no?

November 25, 2019 | Dina Tiniakos and Laurent Castera
Liver biopsy for evaluation of fibrosis in chronic liver disease: Yes or no?
Liver biopsy for evaluation of fibrosis in chronic liver disease: Yes or no?

Chronic liver disease affects many millions of people worldwide and is a major cause of premature death. Assessing liver fibrosis in patients with chronic liver disease can determine disease stage and progression, and also response to therapy, but whether this is best performed via a liver biopsy or noninvasive methods is a matter for debate.

Here, two European experts present their opposing viewpoints on how to assess fibrosis in the setting of chronic liver disease.

Yes—Dina Tiniakos

Biopsy is the reference method for evaluating liver fibrosis and the ‘gold standard’ against which noninvasive methods are compared. The histological stage of fibrosis is one of the most important prognostic factors in patients with chronic liver disease, independent of aetiology. Advanced fibrosis is a strong prognostic factor in alcohol-related liver disease and the most important prognostic indicator in nonalcoholic fatty liver disease (NAFLD), where individual histological fibrosis stages are associated with distinct patient outcomes. 

Liver biopsy is the only way to diagnose nonalcoholic steatohepatitis (NASH) and, generally, offers the added value of assessing disease severity, highlighting possible concurrent disease and evaluating fibrosis progression or regression in paired biopsy samples. The known limitations of sampling and interobserver variability are minimized by high-quality biopsy techniques (using ≤16-gauge needles, core length >15 mm) and evaluation by expert hepatopathologists. Recently, digital image analysis and second harmonic generation technology have enabled objective quantitative and qualitative assessment of liver tissue collagen and can highlight subtle differences in fibrosis between biopsy samples. 

Noninvasive methods of assessing liver fibrosis are widely used with increasing accuracy for diagnosing the absence of fibrosis or presence of severe fibrosis/cirrhosis and, therefore, are helpful to select patients for liver biopsy. However, noninvasive methods cannot distinguish intermediate stages of fibrosis and some serum marker measurements may reflect fibrotic processes in other organs. Failure of application (2–5%), unreliable results (11–15%) and false-positive results in acute inflammation, cholestasis or liver congestion are known limitations of transient elastography, while the patented serum markers have limited availability. While noninvasive tests reduce the need for liver biopsy for fibrosis evaluation they cannot replace it.


No–Laurent Castera

Over the past decade, there has been growing interest in novel noninvasive strategies for the evaluation of fibrosis, given the well-known limitations of taking liver biopsy samples — invasiveness, limited patient acceptance, rare but potentially life threatening complications, sampling variability, pathologist experience, and cost. Taking liver biopsy samples also appears unrealistic considering the magnitude of the nonalcoholic fatty liver disease (NAFLD) epidemic, with around 25% of the general population affected in Western countries.<(p>

Noninvasive testing currently relies on two different but complementary approaches: measuring the levels of serum biomarkers and estimating liver stiffness using ultrasound-based elastography techniques, with transient elastography (FibroScanTM) being the pioneer. Although these two approaches are complementary, they are based on different rationales and concepts. Transient elastography measures liver stiffness related to elasticity, which corresponds to a genuine and intrinsic physical property of the liver parenchyma. By contrast, serum biomarkers are combinations of several, not strictly liver-specific, blood parameters that are optimized to predict the stages of fibrosis as assessed by liver biopsy. 

The most validated noninvasive biomarker tests are FIB-4, AST to platelet ratio index (APRI), NAFLD fibrosis score (nonproprietary formula) and FibroTestTM (proprietary), while FibroScanTM is the most validated elastography technique. All these tests are better at ruling severe fibrosis-cirrhosis out than ruling it in. They also have prognostic value in the context of cirrhosis. For instance, they are able to identify the subgroup of NAFLD patients at high risk of developing liver-related complications and death. As a result, noninvasive tests are now widely used in routine clinical practice and included in national and international guidelines.

References

  • Almpanis Z, Demonakou M and Tiniakos D. Evaluation of liver fibrosis: "Something old, something new…". Ann Gastroenterol 2016; 29: 445–453. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5049550/
  • Lackner C and Tiniakos D. Fibrosis and alcohol-related liver disease. J Hepatol 2019; 70:294–304. https://www.journal-of-hepatology.eu/article/S0168-8278(18)32618-7/fulltext
  • European Association for the Study of the Liver and Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol 2015; 63: 237–264. https://www.journal-of-hepatology.eu/article/S0168-8278(15)00259-7/fulltext
  • Castera L, Friedrich-Rust M and Loomba R. Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease. Gastroenterology 2019; 156: 1264–281. https://www.gastrojournal.org/article/S0016-5085(19)30051-4/fulltext
 
Social Sharing
  • About the Authors
About the Authors

Dina Tiniakos, MD, PhD, FRCPath is Professor of Pathology, Aretaieion Hospital, National & Kapodistrian University of Athens, Greece and senior academic at the Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, UK. She specialises in digestive diseases and her primary expertise is liver pathology with a research focus on fatty liver disease, autoimmune liver diseases and liver cancer. She is Past President of the European Society of Pathology (2019–2021).

Laurent Castera, MD, PhD is Professor of Hepatology at Hôpital Beaujon, Université Paris Diderot, Clichy, France. His clinical and research interests include noninvasive tests for evaluation of liver disease severity and nonalcoholic fatty liver disease. He was President of the European Association for the Study of the Liver (EASL) from 2015 to 2017.

Comment

Please log in with your myUEG account to post comments.

Related Articles
Press Release
Alcohol consumption and poor nutrition across Europe inflicting huge liver disease burden, warn leading experts
Mistakes in...
Mistakes in liver transplantation and how to avoid them
Blog
This is the age of liver biomarkers—let the sunshine in!
Blog
Non-alcoholic fatty liver disease and diabetes—are they symptoms of gut dysbiosis?
Latest Articles
Head-to-Head
Achalasia: Physician versus Surgeon
Subscribe
Sign up with your email to receive UEG news and updates. We respect your privacy.

UEG Secretariat

United European Gastroenterology

Wickenburggasse 1
1080 Vienna, Austria



T: +43 1 997 1639
F: +43 1997 1639 10

UEG Week Registration

Mondial Congress & Events

Official UEG Week Registration Partner
Operngasse 20b
1040 Vienna, Austria



T: +43 1 5880 4 0
F: +43 1 5880 4 185

More

Imprint

Terms & Conditions

Media Policies

Privacy Policy

Social Media

16 827 Followers

11 158 Followers

1 784 Followers

1 870 Subscribers

UEG copyright 2021. All rights reserved. Use of this website constitutes acceptance of the Privacy Policy and Terms & Conditions.